Resources Contact Us Home
Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety

Image Number 13 for United States Patent #8119616.

The present invention relates to a composition comprising an inclusion complex of a cyclodextrin and quinazoline containing zinc-binding moiety based derivatives. The cyclodextrin is preferable a .beta.-cyclodextrin or a derivative thereof. The quinazolines have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.

  Recently Added Patents
Phase locking loop
Self-correcting amplifier system
Peer-to-peer, internet protocol telephone system with proxy interface for configuration data
Mask and method for forming the mask
Methods and systems for motion estimation with nonlinear motion-field smoothing
Identification of biomarkers in biological samples and methods of using same
Lens driving device
  Randomly Featured Patents
Electronic gaming method and system having variable game display timer
Multicast relay for mobile devices
Switch and remote controller using the same
System for identifying a responding station for a radio communications system
Phase modulator
Method of constructing a reusable in-line skate wheel
Glutaraldehyde plus alcohol product
Integrated liquid level and auxiliary sensor system and method
Phase-locked loop apparatus using an embedded oscillator as a lock detection means